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Abstract
Greater than 75% of all hematologic malignancies derive from germinal center (GC) or post-GC B cells, suggesting that the
GC reaction predisposes B cells to tumorigenesis. Because GC B cells acquire expression of the highly mutagenic enzyme
activation-induced cytidine deaminase (AID), GC B cells may require additional DNA repair capacity. The goal of this study
was to investigate whether normal human B cells acquire enhanced expression of DNA repair factors upon AID induction.
We first demonstrated that several DNA mismatch repair, homologous recombination, base excision repair, and ATR
signaling genes were overexpressed in GC B cells relative to naı ¨ve and memory B cells, reflecting activation of a process we
have termed somatic hyperrepair (SHR). Using an in vitro system, we next characterized activation signals required to induce
AID expression and SHR. Although AID expression was induced by a variety of polyclonal activators, SHR induction strictly
required signals provided by contact with activated CD4
+ T cells, and B cells activated in this manner displayed reduced
levels of DNA damage-induced apoptosis. We further show the induction of SHR is independent of AID expression, as GC B
cells from AID -/- mice retained heightened expression of SHR proteins. In consideration of the critical role that CD4
+ T cells
play in inducing the SHR process, our data suggest a novel role for CD4
+ T cells in the tumor suppression of GC/post-GC B
cells.
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Introduction
Among all types of hematologic malignancies, more than 75%
of patients in the United States are classified as having non-
Hodgkin’s lymphomas, Hodgkin’s disease, chronic lymphocytic
leukemia, or multiple myeloma [1,2]. Of note, each of these derive
from germinal center (GC) or post-GC B cells, thereby raising the
important question of what makes mature B cells so uniquely
predisposed to malignant transformation. The likely answer is that
the GC reaction itself renders B cells highly susceptible to
acquisition of non-immunoglobulin mutations and genomic
instabilities [3,4,5,6,7], and therefore functions as the ‘‘bottleneck’’
of the genetic wellness of B lineage cells. Consistent with this
notion, various cytogenetic abnormalities are notoriously associ-
ated with this group of malignancies. However, it remains unclear
how the mutations and/or genomic instabilities that are the
inevitable by-product of the genome-altering process of somatic
hypermutation are suppressed during normal GC reactions, and
how this tumor suppression mechanism fails in B lineage
malignancies. To better understand these questions, it is essential
to study in greater depth the mechanisms governing DNA repair
in GC B cells.
In all somatic cells, there is a delicate balance between ongoing
levels of DNA damage and repair activity mediated by
constitutively expressed DNA repair proteins. The consequences
of upsetting this balance by increasing the level of DNA damage or
by mutational inactivation of DNA repair genes are highly
deleterious and result in the development of cancers in humans
and in mouse models [8,9,10,11]. Furthermore, many human
sporadic cancers also possess hallmarks of DNA repair deficiencies
such as cytogenetic abnormalities, microsatellite instability (MSI),
and resistance to DNA damaging therapies [12]. GC B cells have
an added burden to contend with, i.e., collateral DNA damage
induced by the highly mutagenic enzyme, AID. AID is necessary
for the physiological somatic hypermutation (SHM) and class
switch recombination (CSR) of immunoglobulin (Ig) genes, and it
is now known that AID also causes pathogenic off-target mutations
to many other genomic loci [5,13] and results in tumor
development [14,15,16] and progression [17]. The additional
burden of AID’s mutagenic activity raises the tantalizing possibility
that B lineage cells require significant additional repair capacity
supplementary to constitutively expressed DNA repair factors in
order to maintain the tumor suppression balance. We hypothesize
that such additional DNA repair capacity results from the
temporal induction of expression of various DNA repair genes
specifically in GC B cells, and we term this putative tumor
suppressive DNA repair mechanism somatic hyperrepair (SHR).
In this study, we demonstrate the existence, composition, and
function of SHR in GC B cells and discuss its possible role in the
development of certain hematologic malignancies.
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Ethics statement
Mayo Clinic Institutional Review Board approval was obtained
for use of human blood and tonsil tissue. Informed consent was not
required as this material is considered by the Institutional Review
Board as waste material generated during either blood donation or
surgery. In addition, patient samples arrive de-identified in the
laboratory. Institutional Animal Care and Use Committee
(IACUC) approval (Mayo Clinic IACUC protocol number
A14207) was obtained for studies involving B lymphocytes isolated
from mice. Mice were maintained under clean housing conditions
at all times with no more than 5 mice per cage. Mice were
euthanized under conditions of gradually increasing concentra-
tions of CO2 according to Mayo Clinic IACUC guidelines.
Cells
Mononuclear cells were isolated using Ficoll-Hypaque gradient
centrifugation. Human B cells were enriched to .98% purity by
magnetic cell separation using a Human B Cell Enrichment kit
(StemCell Technologies, Vancouver, British Columbia, Canada).
Human B cell subsets were then further purified into naı ¨ve (IgD
+/
CD38
2/CD27
2), GC (CD19
+CD38
+) and memory (IgD
2/
CD38
2/CD27
+) populations by FACS sorting on a FACSAria
Cytometer (BD, San Jose, CA). Tonsillar GC B cell subset
centroblasts (CB) and centrocytes (CC) used in realtime PCR
assays were purified as previously described [18]. Autologous
CD4
+ T cells used for B/T cell coculture were purified from blood
mononuclear cells using a human CD4
+ T Cell Enrichment kit
(StemCell Technologies). As a source of primary naı ¨ve and
memory B cells, we used C57BL/6 wildtype or AID
2/2 (kindly
provided by Dr. T. Honjo) mice. Following euthanasia as
described above, murine naı ¨ve (B220
+/GL7
2) and GC (B220
+/
GL7
+) B cells were purified by FACS sorting from Peyer’s patch
mononuclear cells isolated from wildtype or AID
2/2 mice. All
antibodies used in FACS analysis and sorting were purchased from
BD Biosciences (San Jose, CA).
B cell in vitro activation conditions
Three-day in vitro activation of human B cells was carried out
essentially as described [19]. Briefly, purified B cells were
stimulated for 3 days with 2.5 mg/ml of CpG (oligodeoxynucleo-
tide 2006, 59-TCGTCGTTTTGTCGTTTTGTCGTT, synthe-
sized by an in-house core facility), 0.5 mg/ml shrCD40L/TNF-
related activation protein (Fitzgerald Industries International,
Acton, MA), 2 mg/ml of polyclonal anti-Ig (agonistic anti-IgA,
IgG, IgM F(ab’)2 Abs; Jackson ImmunoResearch Laboratories,
Inc., West Grove, PA); anti-Ig/CD40 ligand (2 mg/ml agonistic
anti-IgA, IgG, IgM F(ab’)2 Abs and 0.5 mg/ml shrCD40L/TNF-
related activation protein) in the presence of IL2 (20 U/ml;
PeproTech, Rocky Hill, NJ) and IL10 (50 ng/ml; PeproTech). For
the activation of B cells through co-culturing with activated T cells,
6-well microtiter plates were coated with 10 mg/ml anti-human
CD3 (clone UCHT1, R&D Systems, Minneapolis, MN) and
10 mg/ml anti-human CD28 (BD Biosciences) in PBS at 4uC
overnight. Two million purified B cells and 4610
6 autologous
CD4
+ T cells were co-cultured in anti-CD3/anti-CD28 coated
wells for 3 days in the presence of 20 U/ml IL2 and 50 ng/ml
IL10. Activated B cells and T cells were re-purified upon harvest
using B cell and T cell enrichment kits, respectively. For B and T
cell coculture in transwells, 4610
6 purified CD4 T cells were pre-
seeded into anti-CD3/anti-CD28 coated wells for 2 hours before
adding purified B cells into the upper transwell (pore size of
0.4 mm, Corning Inc., Corning, NY) compartment.
DNA damage-induced cell apoptosis
Purified peripheral blood B cells were activated in vitro with
either 2.5 mg/ml CpG or by co-culturing with anti-CD3/CD28
activated CD4
+ T cells for 2 days in the presence of 20 U/ml of
IL2 and 50 ng/ml of IL10. The DNA damaging agents
doxorubicin or cisplatin were added to activated B cells to reach
the final concentration of 0.5 mM and 20 mM, respectively. After
an additional 24 hours in culture, B cell apoptosis was assessed by
FACS analysis using annexin-FITC (Invitrogen, Carlsbad, CA)/
propidium iodide/CD19-allophycocyanin staining.
Immunohistochemistry (IHC) staining
Conventional IHC staining on paraffin-embedded tonsillar
tissue sections was carried out using an automatic processor and
monoclonal anti-MLH1, anti-MSH2 and anti-MSH6 primary
antibodies from Biocare Medical (Concord, CA); primary anti-
AID antibody from Cell Signaling (Danvers, MA); and HRP-
conjugated secondary antibody (Biocare). Stained sections were
then developed with Betazoid DAB as a chromogen (Biocare).
Western blotting
Protein extracts from B cell subsets or chromatin pellets were
analyzed by Western blotting as described elsewhere [20]. Probing
antibodies against human b-actin, MSH2, MSH6, MLH1, PMS2,
UNG, RAD51, ATM, MRE11, RAD50, NBS1, Ku70, and Ku80
were from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-
RPA1 and anti-CHK1 antibodies were purchased from R&D
Systems (Minneapolis, MN). Anti-ATR and anti-BRCA1 were
kindly provided by Dr. Zhenkun Lou (Mayo Clinic).
Real-time RT-PCR
One microgram of total RNA isolated using TRIzol reagent
(Invitrogen) was used for reverse transcription using the First
Strand cDNA kit from GE Healthcare (Piscataway, NJ). The
resulting cDNA was diluted into a final volume of 200 ml, of which
5 ml was then used for a 20 ml PCR reaction with 4 pmols of
primers. DNA repair primers and RT
2 SYBRHGreen master mix
were purchased from SABiosciences (Frederick, MD) while
common primers for both mouse and human AID were
synthesized in-house (hmAID-F: CCAWTTCAAAAATGTCCG-
CTGGGC; hmAID-R: AGGAGGTGAACCAGGTGACGCG).
Real-time PCR was run in a 384-well plate on an ABI Prism
7900HT RealTime System (Applied Biosystems, Foster City, CA).
Chromatin fractionation assay
Chromatin fractionations were carried out essentially as
described previously [21] using 4610
6 purified B cells.
Results
Expression of select DNA repair pathway proteins is
induced in GC B cells
Gene targeting studies in mice have shown that DNA mismatch
repair (MMR) genes are indispensable for SHM, CSR, and
lymphoma suppression of B cells [9,22,23], and that even MMR
haploinsufficient mice exhibit subtle phenotypes [9,23]. These
observations reveal that MMR plays a critical role within B cells
and further suggests that MMR functions in a dose-dependent
manner. We therefore hypothesized that the expression levels of
MMR components and other DNA repair pathway proteins would
increase in GC B cells and constitute the postulated SHR
apparatus. Therefore, we first examined the expression levels of
MMR proteins in GCs of human tonsillar tissue sections by IHC.
Induction of SHR during B Cell GC Responses
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MSH6, and MLH1) were highly expressed in the majority of cells
localized within the tonsillar GC compartment (Figure 1A) and the
pattern of expression was similar to that of AID, a known GC B
cell specific protein. Furthermore, MMR proteins were expressed
within the nucleus (data not shown), a pattern of expression that is
similar to constitutively expressed MMR proteins [20]. These data
demonstrate that MMR factors are indeed robustly induced and
properly localized in a group of GC cells.
To determine if the cells overexpressing MMR proteins were
indeed GC B cells and to determine if other DNA repair factors
were also induced in these cells, we next systematically evaluated
the expression of key DNA repair proteins of various pathways in
purified tonsillar naı ¨ve, GC, and memory B cell subsets. As
expected, the MMR proteins MSH2, MSH6, MLH1, and PMS2
were indeed highly expressed in purified GC B cells compared to
expression levels in naı ¨ve B cells (Fig. 1B), suggesting that GC B
cells have been induced to express significantly elevated levels of
MMR proteins. Moreover, we observed that many other DNA
repair proteins were also induced similarly in GC B cells, including
the base excision repair (BER) factor UNG, homologous
recombination (HR) protein RAD51, single strand DNA binding
protein RPA1, and single strand DNA break signaling molecules
ATR, BRCA1, and CHK1. Furthermore, expression levels of
these DNA repair proteins return to naı ¨ve B cell levels in memory
B cells, with the exception of UNG and RPA1 proteins that
remain moderately expressed, suggesting the induction of these
DNA repair proteins is GC B cell specific. Strikingly, key
components of the non-homologous end joining (NHEJ) pathway,
Ku70 and Ku80, and factors of the double strand DNA break
(DSB) signaling pathway MRE11, NBS1, RAD50, and ATM,
were not detectably induced in GC B cells, but instead were
abundantly expressed in a constitutive manner in all B cell subsets.
Our results suggest that the select DNA repair systems, MMR,
HR, BER and the ATR signaling pathway, collectively constitute
the SHR apparatus in GC B cells.
To determine if the induction of SHR factors occurs at the
transcriptional level in GC B cells, we used real-time RT-PCR to
quantify the relative expression of mRNA of the repair genes of
interest in purified tonsillar naı ¨ve, GC, and memory B cells. With
the exception of PMS2 and ATR, we found that the mRNA levels
of SHR factors were in full accordance with their protein
expression (Fig. 2) suggesting the induction occurred at the
transcriptional level. With respect to PMS2, it is known that its
expression is regulated at the protein level [24]. Consistent with
protein expression levels, the NHEJ repair and DSB checkpoint
components were not induced at the mRNA level either. Our data
are also in agreement with previous microarray studies [18,25]
showing that some DNA repair factors along with other genes are
overexpressed in GC B cells. Taken together, we have demon-
strated that components of the MMR, HR, and BER pathways
and ATR DNA damage checkpoint are selectively induced in GC
B cells, collectively constituting the GC-specific SHR machinery.
SHR proteins are engaged in DNA repair resulting in
higher DNA repair capacity
We next asked if the induction of SHR proteins is associated
with their DNA repair functions in GC B cells in vivo. The total
cellular pool of SHR proteins, like other DNA repair proteins, is
likely to exist in a soluble form as well as an insoluble form
(chromatin-bound). Regarding the latter, it has been suggested
that the level of chromatin-bound DNA repair proteins is a steady-
state representation of endogenous ongoing DNA repair activity
[26,27]. We took advantage of this knowledge to address this
question, and we first determined the levels of MSH2, MLH1, and
RAD51 proteins associated with chromatin. As presented in
Figure 3, after stringent extraction and washing, significantly
higher levels of MSH2, MLH1, and RAD51 remained in the
chromatin-bound fraction in GC B cells as compared with naı ¨ve
and memory B cells. These results suggest that the newly induced
levels of SHR factors are actively participating in GC B cell DNA
repair. At the same time, we also performed in vitro DNA mismatch
repair activity assay on the soluble fractions, and we found that
Figure 1. DNA repair proteins are selectively overexpressed in
GC B cells. A. IHC staining of tonsillar tissue sections with antibodies
against DNA mismatch repair proteins MSH2, MSH6, MLH1, and AID. B.
Western detection of various DNA repair proteins in total tonsillar B cells
(presort), naı ¨ve (N), GC, and memory (M) B cells. The data are
representative of three independent experiments.
doi:10.1371/journal.pone.0015549.g001
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activity than did similar fractions isolated from naı ¨ve and memory
B cells. Thus, we observed on average, a 3.5-fold higher level of
activity in GC B cells; however, this was somewhat variable
between experiments (data not shown). Taken together, our data
are compatible with the notion that increased expression of SHR
proteins does result in a heightened level of DNA repair activity in
GC B cells.
Induction of SHR and induction of AID are independent
processes
Because AID imposes a great genotoxic stress on GC B cells, we
next questioned if the induction of SHR factors was simply a stress
response to AID-mediated DNA lesions. To that end, we
quantitated mRNAs of various DNA repair factors and AID in
naı ¨ve and GC subsets isolated from wildtype or AID
2/2 mice. In
wildtype mice, GC B cells expectedly expressed about 40-fold
Figure 2. Real-time RT-PCR quantification of mRNA of SHR repair genes in tonsillar naı ¨ve (N), GC centroblast (CB), GC centrocyte
(CC) and memory (M) B cells. Three tonsil pools each prepared from 6 individual tonsils were used. Genes induced transcriptionally in GC B cells
are marked with the red circles while the ones not induced are highlighted with the blue circles. Statistical significance: *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0015549.g002
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MSH2, MSH6, MLH1, and UNG transcripts compared with
naı ¨ve B cells. In AID
2/2 mice, however, GC B cells displayed
similar induction levels of the SHR factors MSH2, MSH6, MLH1,
RAD51, and UNG as compared to naı ¨ve B cells (Fig. 4),
suggesting that the programmed SHR induction is neither due to
the stress response of AID-mediated DNA lesions nor due to any
other AID-mediated mechanisms. Interestingly, we also noticed
that the absolute mRNA levels of those repair factors are higher in
both naı ¨ve and GC B cells of AID
2/2 mice compared to that of
wildtype mice. This may reflect ongoing hyperplasia reportedly
occurring in lymphoid follicles of AID
2/2 mice [28].
SHR is specifically induced through CD4
+ T cell-
dependent B cell activation
Several studies have shown that various B cell stimuli can
induce AID expression in vitro prompting us to ask what signaling
pathway(s) leads to the induction of SHR. To address this
question, we activated pure peripheral blood B cells in vitro with
various stimuli, attempting to reconstitute at least in part B cell
activation events of the GC. As shown in Fig. 5A, AID expression
was readily induced by all stimuli including co-culture with
activated CD4
+ T cells. Surprisingly, significant induction of SHR
factors was only observed when resting B cells were activated by
co-culture with activated CD4
+ T cells, while stimulation with
CpG, CD40L, anti-Ig, or CD40L/anti-Ig had little effect on the
expression of SHR factors. Such induction could not come from
the residual contaminating T cells since those DNA repair genes
are not induced in activated T cells (Fig. 5A, far right column). Of
note, although post-cocultured T cells did show some AID activity,
we attribute this to the presence of a small number of
contaminating B cells as the result of imperfect B/T cell separation
following coculture. In addition, when CD8
+ T cells were used
instead for the coculture, SHR induction in B cells was not
detected (data not shown). This observation suggests that AID and
SHR are each activated through distinct GC-specific signaling
pathways, and that unique signals from CD4
+ T cells are necessary
to activate SHR in B cells. However, co-culturing B and T cells in
transwells was not sufficient to activate the induction of SHR
suggesting that physical contact between B and T cells is necessary
(Fig. 5B). Among the B cell stimuli employed, CpG stimulation
induced the most robust level of B cell proliferation, yet SHR was
not induced under these conditions. This suggests that SHR is not
induced simply as a function of cell proliferation. Overall, these
results suggest that effective tumor suppression of post-GC B cells
may depend on specific signals delivered by CD4
+ T cells.
SHR protects B cells from DNA damage-induced
apoptosis
Ideally, DNA damage is faithfully repaired. However, it is also
possible that repair is imprecise and results in oncogenic mutations
and ultimately transformation, or cell apoptosis if the damage is
irreparable. We hypothesized that SHR would mitigate or
attenuate both of the latter events. To address this hypothesis,
we first asked whether induction of SHR would protect B cells
from DNA damage-induced apoptosis. To that end, we activated
purified peripheral blood B cells in vitro and then challenged the
activated B cells with DNA-damaging agents doxorubicin or
cisplatin. As shown in Fig. 6, when B cells were activated with
CpG, a stimulus shown to lack the ability to induce SHR (Fig. 5),
cells were very sensitive to the treatment with either doxorubicin
Figure 3. Induced SHR proteins in GC B cells are associated
with chromatin, indicative of functional engagement in DNA
repair in vivo. Western blot detection of various DNA repair proteins in
insoluble chromatin fractions of total tonsillar (presort), naı ¨ve (N), GC,
and memory (M) B cells.
doi:10.1371/journal.pone.0015549.g003
Figure 4. Induction of SHR is AID-independent. Peyer’s patch
naı ¨ve (B220
+/GL7
2) or GC (B220
+/GL7
+) B cells from AID
+/+ or AID
2/2
mice were FACS-sorted, and mRNA levels were then quantitated using
real-time RT-PCR. The data are representative of two independent
experiments each using Peyer’s patches pooled from 6 mice.
doi:10.1371/journal.pone.0015549.g004
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PLoS ONE | www.plosone.org 5 December 2010 | Volume 5 | Issue 12 | e15549Figure 5. Ex vivo induction of SHR and AID. A. Purified peripheral blood B cells were stimulated with CpG, CD40 ligand, and/or anti-Ig, in the
presence of IL2 and IL10 for 3 days, or coculture with anti-CD3 and anti-CD28 activated CD4 T cells for 3 days. B. B cells were activated by anti-CD3
and anti-CD28 activated CD4 T cells through direct coculture, transwell coculture, or activated with CpG for 3 days. Expression of select representative
SHR genes were analyzed in activated B cells and activated T cells as a control (B cells and T cells were repurified when T/B direct coculture was the
mode of activation) by real-time RT-PCR.
doi:10.1371/journal.pone.0015549.g005
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with activated CD4
+ T cells, a stimulus that induces the expression
of SHR proteins, B cell sensitivity to doxorubicin- and cisplatin-
induced apoptosis was significantly reduced. These data further
complement our earlier observations suggesting that SHR
induction results in heightened DNA repair capacity in GC B cells.
Discussion
Mounting evidence has shown that expression of AID in GC B
cells poses a serious threat to genomic integrity and may induce
oncogenesis unless there is additional DNA repair capacity. Here
we show that GC B cells are indeed induced by specific signals to
express increased levels of various DNA repair pathway factors.
We postulate this occurs specifically to counteract the mutational
threat posed by AID, a mechanism we have termed as SHR. We
further demonstrated that SHR collectively consists of MMR,
BER, HR and ATR signaling pathways. It is important to note
that elevated expression of a single DNA repair protein is unlikely
to result in enhanced DNA repair activity unless this protein plays
a rate-limiting role in the repair pathway. However, our data
demonstrating that a panel of pathway-wide factors is simulta-
neously induced suggests that this response likely does result in
higher repair activities. Indeed, our preliminary DNA repair
activity data taken together with data obtained from our DNA
damage protection assays provide support for the notion that SHR
is functionally significant to GC B cells. Moreover, our data are
consistent with a previous observation that DNA repair is not
deficient in GC B cells [29] and we further extend this work by
showing that GC B cell repair capacity is not merely equivalent to
naı ¨ve and memory B cells, but instead is significantly increased.
In addition to increases in DNA repair capacity, increases in
DNA repair fidelity are also necessary to suppress the accumu-
lation of mutations. The SHR machinery achieves these twin goals
by the selective inclusion of high fidelity DNA repair pathways.
While both NHEJ/ATM and HR/ATR axes can repair blunt end
DSBs [30], SHR induces the error-free HR/ATR repair axis
rather than the error-prone NHEJ/ATM pathway. SHR’s
selective inclusion of high fidelity DNA repair proteins is entirely
consistent with its proposed mutation avoidance role in tumor
suppression of post-GC B cells.
It is known that expression of DNA repair genes can be
regulated by cell cycle regulators and that GC B cells are
undergoing extensive cell proliferation. However, it is unlikely that
SHR induction resulted from cell cycle effects in these experi-
ments, since the other B cell stimulators employed in this study,
i.e., CpG, CD40L, and anti-Ig, induced robust B cell proliferation
yet still did not induce SHR expression. Furthermore, the selective
nature of the DNA repair pathway induction in GC B cells
suggests a mechanism with more specificity than the global
changes accompanying proliferation. It would be interesting to
characterize the cell proliferation profile and cell cycle character-
istics of the SHR-expressing B cell subset, however, this will
require the use of monoclonal B cells from mice or use of human B
cell lines which may not be representative of normal GC B cells.
We recognize that some of the SHR genes remain moderately
expressed in newly emerged tonsillar memory B cells, though they
are clearly downregulated in more mature subsets. This interme-
diate expression may reflect a real physiologic kinetic phenomenon
in which CD27 induction on memory B cells and extinction of
SHR are somewhat temporally staggered or may simply reflect the
imperfect separation between GC and memory B cells during cell
isolation. In either case, the clear distinction between GC and
mature memory B cells implicate SHR as a GC-specific event.
Our data indicate that ATR is induced at the protein level but
not at the transcriptional level while the other ATR pathway
proteins, CHK1 and BRCA1, are induced at both levels.
Recently, Melnick and colleagues described a feedback loop in
which the transcriptional repressor BCL6 represses the expression
of ATR and CHK1 in GC B cells [31,32]. These findings do not
contradict our data since it remains possible that ATR and CHK1
are expressed at induced levels in GC B cells relative to expression
levels in naı ¨ve and memory B cells despite coincident BCL6
repression. Furthermore, the authors made another important
observation that BCL6-mediated ATR repression is rather brief
and is readily overridden by CD40 signaling, the major co-
stimulatory signaling pathway triggered by CD4
+ T cell engage-
ment. Consistent with this notion and with our results, microarray
analysis showed that CHK1 expression levels were indeed induced
in GC B cells as compared with naı ¨ve and memory B cells [18].
Under normal circumstances, B cell encounters with CD4
+ T
helper cells in the GC results in induction of SHR as well as the
expression of AID. However, our data show that many other B cell
stimuli can activate the expression of AID without the induction of
SHR. The independence of AID and SHR raises the possibility
that stimuli resulting in AID expression unbalanced by SHR may
ultimately lead to DNA repair deficits that may result in
accumulation of mutations. Specifically, this observation predicts
that physiologic circumstances like the opportunistic ligation of
CD40 receptors on B cells by soluble CD40L, the activation of B
Figure 6. SHR functions in protecting B cells from DNA
damage-induced cell apoptosis. Two day-activated peripheral
blood B cells with CpG or coculture with anti-CD3 and anti-CD28
activated T cells were further treated with 0.5 mM doxorubicin or 20 mm
cisplatin. B cell apoptosis was analyzed using Annexin-FITC/PI/CD19-
APC staining. Data include 4 independent experiments.
doi:10.1371/journal.pone.0015549.g006
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receptor by T cell independent antigens may thus be more likely to
result in the oncogenic transformation of B cells. Consistent with
this notion, mice transgenic for CD40L, or CD40L functional
equivalent latent membrane protein 1 (LMP1) of Epstein-Barr
virus do develop various B cell malignancies [33,34]. Similarly, in
vitro experiments have shown that CpG stimulation could readily
induce non-clonal cytogenetic abnormalities suggesting newly
acquired genomic instabilities (Wu et al., submitted for publica-
tion).
It is readily accepted that increased EBV infection in B cells and
weakened immune surveillance play a major role in the increased
incidence of B cell lymphoma in HIV
+ patients. However, it is
difficult to fully explain how EBV negative lymphomas arise in this
population and why perforin knockout mice defective in immune
surveillance only showed a moderate increase of spontaneous B
cell lymphoma at late onset [35]. Our current data suggest a
possible novel function for CD4
+ T cells in suppressing B cell
tumorigenesis, providing a rational complementary and/or
alternative explanation for this lingering paradox. Moreover, our
data also suggest that CD4
+ T cells act as a safeguard to prevent
nonspecific B cell activation leading to imbalanced AID
expression.
With respect to this latter point, it is interesting that some HIV-
related lymphomas exhibit microsatellite instability (MSI) despite
lacking any apparent deficiency of MMR proteins [36]. This
discrepancy suggests that there was a transient MMR deficiency at
some point in the history (likely in GCs) of the malignant B cell.
Our data suggesting that SHR induction is necessary to mitigate
DNA damage in GC B cells such as MSI is consistent with these
observations and offers a novel interpretation that MSI in these
lymphomas was likely acquired during the GC reaction due to
compromised SHR induction rather than from constitutive defects
in MMR. In this regard, gene targeting experiments in mice have
shown that mutations at A/T positions in the neighborhood of
AID target ‘‘C’’ sites are exclusively introduced by the DNA
MMR system during SHM, and that compromised MMR leads to
the reduction of mutation frequencies at A/T positions in Ig genes
[37]. Thus, we hypothesize that if defective SHR induction could
lead to the development of B cell malignancy, those malignant
cells would harbor skewed A/T mutation frequencies in their Ig
genes. One example of such a scenario could be lymphomas that
develop in HIV-infected patients whose SHR-inducing CD4
+ T
cells are severely suppressed. To that end, in preliminary studies,
we analyzed the A/T mutation frequencies of Ig sequences from
17 EBV-negative HIV-related lymphoma samples and 39 Ig
sequences from normal B cells. Our preliminary yet tantalizing
data indicate that A/T mutations in HIV related lymphomas are
indeed skewed in a manner suggestive of compromised SHR when
compared to that of normal B cells (Wu, unpublished data).
However, direct involvement of SHR in lymphomagenesis will
require further thorough investigation, which is currently under
way in our laboratory.
Given our finding that CD4
+ T cells play an essential role in the
induction of SHR in GC B cells, we believe that further
identification of the specific receptors and signaling elements
underlying induction of SHR will broaden our understanding of
the etiology of mature B cell malignancies. Such an understanding
will also enable us to target these molecules therapeutically to
prevent lymphomagenesis in HIV-infected patients and organ
transplant recipients.
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